Whalesbook
Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs), typically on divergent paths, have shown a rare convergence by significantly increasing their holdings in Utkarsh Small Finance Bank Limited and Sai Life Sciences Limited during the July-September quarter. This is noteworthy as FIIs have been net sellers in the broader Indian equity market, offloading Indian equities worth ₹76,609 crore in Q2FY26, while DIIs actively bought domestic equities totalling ₹1.64 lakh crore, supporting the market.
Utkarsh Small Finance Bank, focusing on under-penetrated rural and semi-urban regions, saw DIIs raise their stake by 7.92% points (to 10.70%) and FIIs by 11.22% points (to 13.07%). The bank's strategy involves a diversified asset portfolio, with growth in Micro-banking Business Loans (MBBL) and MSME lending, alongside a growing share of secured loans. However, the bank's asset quality deteriorated in Q2FY26, with Gross Non-Performing Assets (GNPA) rising to 12.4% and Net NPA to 5%, primarily due to slippages in the microfinance segment. The bank also reported a revenue drop of 14.9% and a net loss of ₹348 crore, largely due to bad loan provisions. Management views this quarter as a "reset" with expectations for improvement from Q3FY26. Its Price-to-Book Value (PBV) ratio stands at 1.25, considered fair.
Sai Life Sciences Limited, a global Contract Research, Development, and Manufacturing Organization (CRDMO), attracted substantial investment from both investor types. FIIs increased their stake by 7.92% points to 22.5%, and DIIs by 8.31% points to 29.9%. The company offers a comprehensive suite of services from drug discovery to manufacturing and has a global presence with strong accreditations from USFDA and PMDA. Sai Life Sciences reported robust financials, with sales growing 35.9% YoY to ₹537 crore and profits doubling to ₹84 crore in Q2FY26. The company is undertaking a ₹700 crore capex plan to expand manufacturing capacities. It trades at a Price-Earnings (PE) ratio of 63.4X, indicating a premium valuation.
Impact: This rare joint endorsement from institutional investors can significantly boost market confidence in Utkarsh Small Finance Bank and Sai Life Sciences, potentially driving positive stock performance. It highlights how discerning investors are looking beyond current financials to future growth potential, identifying opportunities in sectors like rural banking and specialized pharmaceutical services. The co-investment pattern provides valuable insights for other investors on where institutional money is flowing.
Rating: 7/10
Terms Explained:
FIIs (Foreign Institutional Investors): Overseas entities that invest in the securities of another country.
DIIs (Domestic Institutional Investors): Indian entities like mutual funds, insurance companies, and banks that invest in domestic securities.
Q2FY26: The second quarter of the financial year 2025-2026, typically from July to September.
CRDMO (Contract Research, Development, and Manufacturing Organization): A company that provides research, development, and manufacturing services for the pharmaceutical industry on a contract basis.
MSME (Micro, Small, and Medium Enterprises): Classification of businesses based on their size and revenue.
GNPA (Gross Non-Performing Assets): The total value of loans that are in default or are unlikely to be repaid by the borrower.
Net NPA (Net Non-Performing Assets): Gross NPAs minus provisions made by the bank for these bad loans.
PBV (Price-to-Book Value) Ratio: A valuation metric that compares a company's market capitalization to its book value.
PE Ratio (Price-to-Earnings Ratio): A valuation metric that compares a company's share price to its earnings per share.
JLG (Joint Liability Group): A group of borrowers who are jointly liable for each other's loans, often used in microfinance.
MBBL (Micro-banking Business Loan): Loans provided to individuals or small businesses in the microfinance segment.
USFDA (United States Food and Drug Administration): A federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, etc.
PMDA (Pharmaceuticals and Medical Devices Agency): Japan's regulatory agency responsible for pharmaceuticals and medical devices.
API (Active Pharmaceutical Ingredients): The biologically active component of a drug product.